Molecular Mechanisms And Functional Consequences - Understanding Endocrine Tumorigenesis
Funder
National Health and Medical Research Council
Funding Amount
$124,530.00
Summary
A/Prof Marsh is focused on discovering the causes of both inherited and non-inherited endocrine tumours, translating this knowledge into medical practice for the improved diagnosis of cancer and using this knowledge to highlight new therapeutic options for people who have cancer. She is internationally recognised for her work on a protein linked to the development of parathyroid cancer and is working towards improving our understanding of women’s cancers.
Prof. Simes will lead and develop research at the NHMRC Clinical Trials Centre in collaboration with major national and international cooperative groups. Research themes include integrating molecular science with trial design and embedding research routinely in health care. Projects include surgery for rectal cancer; novel targeted therapy in gastric cancer; aspirin to prevent colon cancer; placental transfusion for preterm babies; risk in heart disease; economic assessment of clinical trials.
Defining The Role Of The PSA-related Kallikrein Serine Proteases In Hormone Dependent Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$880,454.00
Summary
Kallikreins are a family of 15 proteins, related to the prostate cancer biomarker PSA, that have potential as biomarkers for hormone dependent cancers such as prostate and ovarian cancer. Prof Judith Clements and her team discovered that kallikreins induce resistance to chemotherapy in ovarian cancer and are found in prostate cancer bone disease. Her research will determine the underlying mechanisms of kallikrein action and their potential as new biomarkers or treatment targets for these disease ....Kallikreins are a family of 15 proteins, related to the prostate cancer biomarker PSA, that have potential as biomarkers for hormone dependent cancers such as prostate and ovarian cancer. Prof Judith Clements and her team discovered that kallikreins induce resistance to chemotherapy in ovarian cancer and are found in prostate cancer bone disease. Her research will determine the underlying mechanisms of kallikrein action and their potential as new biomarkers or treatment targets for these diseases.Read moreRead less
My goal is to boost the immune system against cancer to develop new therapies. I aim to do this by genetically engineering the immune system and using drugs to help strengthen white blood cells of the immune system. Tumors can actively fight immunity by producing suppressive molecules. I am seeking to identify and understand these molecules in order to block them and help the immune system fight cancer. Using this knowledge, I aim to start new clinical trials for cancer.
Prof Lindeman's laboratory, co-headed with Dr Visvader, has played an influential role in the identification of mammary stem and progenitor cells, elucidation of the mammary epithelial cell hierarchy and gaining insights into how female hormones regulate mammary gland development and cancer. In parallel, I have established translational research platforms such as patient-derived tumour xenograft (PDX) models, which offer powerful preclinical models to test new drugs.
Rob Ramsay has had a long standing research commitment to understanding bowel and breast cancer using mouse models with defined genetic defects. These sophisticated models replicate various stages of cancer development and some have profound effects on normal tissue biology. He also uses molecular tools to investigate how genes are controlled. These approaches are providing direct input into the development of therapeutic agents for cancer treatment.
Computational Approaches To Making Sense Of Cancer -omics Data
Funder
National Health and Medical Research Council
Funding Amount
$706,370.00
Summary
Evolution is a hallmark of cancer. It underlies tumorigenesis, metastasis, disease progression, the emergence of drug resistance, and patient death. My research will develop the essential bioinformatics methods and computational models to understand cancer evolution using -omics data, and apply these to discover the molecular mechanisms that cause complex genome rearrangements; investigate the evolution of advanced melanoma; and translate our tools and discoveries into the clinical setting.
Deciphering Breast Cancer Heterogeneity To Improve Breast Cancer Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$851,980.00
Summary
Breast cancer is a very heterogeneous disease. Patients are often treated in a ‘one size fits all’ approach, but response to therapy remains quite disparate. To better personalise therapy, there is a pressing need to define the precise cell types and initiating genetic events that give rise to breast cancer. This application is focussed on understanding the molecular and cellular origins of breast cancer, with the potential of identifying new prognostic markers and therapeutic targets.
Growth Regulatory Transcriptional Networks And Novel Therapies In Vascular Pathobiology
Funder
National Health and Medical Research Council
Funding Amount
$576,760.00
Summary
Cardiovascular disease and cancer together account for the majority of all deaths. Underpinning both these conditions are cellular and molecular changes in our blood vessels. This Fellowship will enable Professor Khachigian to enhance our understanding of fundamental mechanisms regulating the pathogenesis of vascular disease, and by harnessing this new knowledge in preclinical and human trials, generate novel strategies to combat a range of diseases through strategic partnership, collaboration a ....Cardiovascular disease and cancer together account for the majority of all deaths. Underpinning both these conditions are cellular and molecular changes in our blood vessels. This Fellowship will enable Professor Khachigian to enhance our understanding of fundamental mechanisms regulating the pathogenesis of vascular disease, and by harnessing this new knowledge in preclinical and human trials, generate novel strategies to combat a range of diseases through strategic partnership, collaboration and training.Read moreRead less
I am a cancer biologist determining the mechanisms controlling growth and proliferation of cancer cells and use transgenic models of malignancy and genetic approaches to identify new therapies for targeting growth control in the treatment of cancer.